25 XP   0   0   10

Seres Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Seres Therapeutics Inc together

PenkeI guess you are interested in Seres Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Seres Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Seres Therapeutics Inc

I send you an email if I find something interesting about Seres Therapeutics Inc.

Quick analysis of Seres Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Seres Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$-0.30
Expected worth in 1 year
$-0.67
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-0.37
Return On Investment
-65.8%

For what price can you sell your share?

Current Price per Share
$0.56
Expected price per share
$0 - $1.01
How sure are you?
50%

1. Valuation of Seres Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$0.56

Intrinsic Value Per Share

$-15.41 - $-9.31

Total Value Per Share

$-15.71 - $-9.60

2. Growth of Seres Therapeutics Inc (5 min.)




Is Seres Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$44.8m$45.5m-$66.9m-314.0%

How much money is Seres Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$28.5m-$63.4m$34.8m122.0%
Net Profit Margin-16,524.8%-4,541.3%--

How much money comes from the company's main activities?

3. Financial Health of Seres Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#986 / 1016

Most Revenue
#195 / 1016

Most Profit
#780 / 1016

Most Efficient
#964 / 1016

What can you expect buying and holding a share of Seres Therapeutics Inc? (5 min.)

Welcome investor! Seres Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Seres Therapeutics Inc.

What can you expect buying and holding a share of Seres Therapeutics Inc?

First you should know what it really means to hold a share of Seres Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Seres Therapeutics Inc is $0.5599. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Seres Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Seres Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.30. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.20 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Seres Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.27-48.8%-0.19-33.6%-0.41-74.0%-0.19-34.8%-0.16-29.1%
Usd Book Value Change Per Share-0.20-35.2%-0.09-16.5%-0.20-35.7%0.000.2%-0.01-1.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.1%
Usd Total Gains Per Share-0.20-35.2%-0.09-16.5%-0.20-35.7%0.000.2%-0.01-1.3%
Usd Price Per Share1.40-3.56-5.64-8.76-10.90-
Price to Earnings Ratio-1.28--0.57--3.46--9.93--18.23-
Price-to-Total Gains Ratio-7.11--5.24--5.83--42.06--111.91-
Price to Book Ratio-4.71--3.59-32.13-6.98-9.28-
Price-to-Total Gains Ratio-7.11--5.24--5.83--42.06--111.91-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.5599
Number of shares1786
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.090.00
Usd Total Gains Per Share-0.090.00
Gains per Quarter (1786 shares)-164.511.89
Gains per Year (1786 shares)-658.057.54
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-658-66808-2
20-1316-13260156
30-1974-198402314
40-2632-264203022
50-3290-330003830
60-3948-395804538
70-4606-461605346
80-5264-527406054
90-5922-593206862
100-6580-659007570

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%2.038.00.05.0%2.039.00.04.9%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%8.030.02.020.0%9.030.02.022.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%1.00.040.02.4%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%8.030.02.020.0%9.030.02.022.0%

Fundamentals of Seres Therapeutics Inc

About Seres Therapeutics Inc

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 14:18:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Seres Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Seres Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Seres Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -64,450.0% means that $-644.50 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Seres Therapeutics Inc:

  • The MRQ is -64,450.0%. The company is making a huge loss. -2
  • The TTM is -16,524.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-64,450.0%TTM-16,524.8%-47,925.2%
TTM-16,524.8%YOY-4,541.3%-11,983.5%
TTM-16,524.8%5Y-4,508.3%-12,016.5%
5Y-4,508.3%10Y-2,432.5%-2,075.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-64,450.0%-199.6%-64,250.4%
TTM-16,524.8%-213.0%-16,311.8%
YOY-4,541.3%-279.3%-4,262.0%
5Y-4,508.3%-438.4%-4,069.9%
10Y-2,432.5%-605.5%-1,827.0%
1.1.2. Return on Assets

Shows how efficient Seres Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Seres Therapeutics Inc to the Biotechnology industry mean.
  • -11.5% Return on Assets means that Seres Therapeutics Inc generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Seres Therapeutics Inc:

  • The MRQ is -11.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.5%TTM-9.9%-1.6%
TTM-9.9%YOY-20.4%+10.5%
TTM-9.9%5Y-12.9%+3.0%
5Y-12.9%10Y-17.6%+4.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.5%-13.5%+2.0%
TTM-9.9%-12.9%+3.0%
YOY-20.4%-11.8%-8.6%
5Y-12.9%-14.1%+1.2%
10Y-17.6%-16.0%-1.6%
1.1.3. Return on Equity

Shows how efficient Seres Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Seres Therapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Seres Therapeutics Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Seres Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM51.5%-51.5%
TTM51.5%YOY-272.6%+324.1%
TTM51.5%5Y-49.1%+100.6%
5Y-49.1%10Y-56.5%+7.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM51.5%-16.1%+67.6%
YOY-272.6%-15.1%-257.5%
5Y-49.1%-19.9%-29.2%
10Y-56.5%-20.9%-35.6%

1.2. Operating Efficiency of Seres Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Seres Therapeutics Inc is operating .

  • Measures how much profit Seres Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Seres Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -68,775.0% means the company generated $-687.75  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Seres Therapeutics Inc:

  • The MRQ is -68,775.0%. The company is operating very inefficient. -2
  • The TTM is -17,628.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-68,775.0%TTM-17,628.2%-51,146.8%
TTM-17,628.2%YOY-4,416.0%-13,212.2%
TTM-17,628.2%5Y-4,698.0%-12,930.1%
5Y-4,698.0%10Y-2,530.1%-2,167.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-68,775.0%-295.1%-68,479.9%
TTM-17,628.2%-225.8%-17,402.4%
YOY-4,416.0%-288.4%-4,127.6%
5Y-4,698.0%-477.4%-4,220.6%
10Y-2,530.1%-625.6%-1,904.5%
1.2.2. Operating Ratio

Measures how efficient Seres Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 688.75 means that the operating costs are $688.75 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Seres Therapeutics Inc:

  • The MRQ is 688.750. The company is inefficient in keeping operating costs low. -1
  • The TTM is 175.974. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ688.750TTM175.974+512.776
TTM175.974YOY45.713+130.262
TTM175.9745Y48.619+127.356
5Y48.61910Y28.316+20.303
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ688.7503.090+685.660
TTM175.9743.264+172.710
YOY45.7133.783+41.930
5Y48.6195.679+42.940
10Y28.3167.894+20.422

1.3. Liquidity of Seres Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Seres Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.78 means the company has $1.78 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Seres Therapeutics Inc:

  • The MRQ is 1.778. The company is able to pay all its short-term debts. +1
  • The TTM is 2.382. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.778TTM2.382-0.604
TTM2.382YOY2.713-0.331
TTM2.3825Y3.079-0.697
5Y3.07910Y6.703-3.624
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7783.914-2.136
TTM2.3824.220-1.838
YOY2.7135.388-2.675
5Y3.0796.045-2.966
10Y6.7036.406+0.297
1.3.2. Quick Ratio

Measures if Seres Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Seres Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.38 means the company can pay off $1.38 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Seres Therapeutics Inc:

  • The MRQ is 1.385. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 2.160. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.385TTM2.160-0.775
TTM2.160YOY3.163-1.004
TTM2.1605Y3.835-1.675
5Y3.83510Y10.427-6.592
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3853.572-2.187
TTM2.1603.998-1.838
YOY3.1635.390-2.227
5Y3.8355.969-2.134
10Y10.4276.287+4.140

1.4. Solvency of Seres Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Seres Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Seres Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.13 means that Seres Therapeutics Inc assets are financed with 112.5% credit (debt) and the remaining percentage (100% - 112.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Seres Therapeutics Inc:

  • The MRQ is 1.125. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.072. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.125TTM1.072+0.053
TTM1.072YOY0.854+0.218
TTM1.0725Y0.981+0.091
5Y0.98110Y0.798+0.182
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1250.336+0.789
TTM1.0720.334+0.738
YOY0.8540.269+0.585
5Y0.9810.366+0.615
10Y0.7980.390+0.408
1.4.2. Debt to Equity Ratio

Measures if Seres Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Seres Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Seres Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.243-4.243
TTM4.243YOY12.190-7.947
TTM4.2435Y3.667+0.576
5Y3.66710Y2.599+1.067
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM4.2430.396+3.847
YOY12.1900.335+11.855
5Y3.6670.434+3.233
10Y2.5990.465+2.134

2. Market Valuation of Seres Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Seres Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Seres Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -1.28 means the investor is paying $-1.28 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Seres Therapeutics Inc:

  • The EOD is -0.512. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.281. Based on the earnings, the company is expensive. -2
  • The TTM is -0.570. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.512MRQ-1.281+0.769
MRQ-1.281TTM-0.570-0.711
TTM-0.570YOY-3.465+2.894
TTM-0.5705Y-9.934+9.363
5Y-9.93410Y-18.228+8.294
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.512-2.259+1.747
MRQ-1.281-2.569+1.288
TTM-0.570-2.664+2.094
YOY-3.465-4.120+0.655
5Y-9.934-6.258-3.676
10Y-18.228-6.171-12.057
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Seres Therapeutics Inc:

  • The EOD is -0.437. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.093. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.606. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.437MRQ-1.093+0.656
MRQ-1.093TTM-0.606-0.486
TTM-0.606YOY-3.524+2.918
TTM-0.6065Y-10.339+9.732
5Y-10.33910Y-20.583+10.245
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.437-2.924+2.487
MRQ-1.093-3.246+2.153
TTM-0.606-3.488+2.882
YOY-3.524-5.620+2.096
5Y-10.339-8.315-2.024
10Y-20.583-8.826-11.757
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Seres Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -4.71 means the investor is paying $-4.71 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Seres Therapeutics Inc:

  • The EOD is -1.885. Based on the equity, the company is expensive. -2
  • The MRQ is -4.713. Based on the equity, the company is expensive. -2
  • The TTM is -3.595. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.885MRQ-4.713+2.828
MRQ-4.713TTM-3.595-1.119
TTM-3.595YOY32.128-35.723
TTM-3.5955Y6.983-10.577
5Y6.98310Y9.283-2.300
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.8851.851-3.736
MRQ-4.7132.090-6.803
TTM-3.5952.095-5.690
YOY32.1282.844+29.284
5Y6.9833.466+3.517
10Y9.2833.815+5.468
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Seres Therapeutics Inc.

3.1. Institutions holding Seres Therapeutics Inc

Institutions are holding 59.484% of the shares of Seres Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Flagship Ventures Management, Inc.15.30833.99362311704500
2023-12-31FMR Inc12.83930.0021193885801578880.821
2023-12-31BlackRock Inc4.86030.00037339454-582474-7.3527
2023-12-31Vanguard Group Inc3.97680.000260053075285639.651
2023-12-31Hudson Bay Capital Management LP2.8610.038443204003208008.0208
2023-09-30Point72 Asset Management, L.P.1.82050.019127491001728700169.414
2023-12-31Bank of America Corp1.56440.00032362449110805488.3337
2023-12-31Millennium Management LLC1.47280.001422240751436053182.2351
2023-12-31Geode Capital Management, LLC1.38670.000320940391064805.3573
2023-12-31State Street Corporation1.26450.00011909524-7626366-79.9754
2023-12-31Eversept Partners, LLC1.16120.21571753538-599018-25.4624
2023-12-31Susquehanna International Group, LLP0.93440.000414110501161237464.8425
2023-12-31Woodline Partners LP0.85440.019612902761090276545.138
2023-12-31Handelsbanken Fonder AB0.72840.0075110000010000010
2023-12-31Morgan Stanley - Brokerage Accounts0.58630.0001885336515938139.6699
2023-12-31Goldman Sachs Group Inc0.57730.000187172417086124.3787
2023-12-31Renaissance Technologies Corp0.5410.00188170008170000
2023-12-31Northern Trust Corp0.51030.0002770611-152050-16.4795
2023-12-31Charles Schwab Investment Management Inc0.44790.0002676387-80180-10.5979
2023-12-31Qube Research & Technologies0.42420.0018640655475113287.0045
Total 54.124.303281726550+676875+0.8%

3.2. Funds holding Seres Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Growth Compy Commingled Pl O5.14720.0113777275700
2024-02-29Fidelity Growth Company Fund3.87410.0112585020000
2024-02-29Vanguard Total Stock Mkt Idx Inv1.96440.0002296650200
2024-03-28iShares Russell 2000 ETF1.56760.0028236721311430.0483
2024-02-29Fidelity Growth Company K61.4280.0134215647500
2024-02-29Fidelity Series Growth Company1.03120.0112155720000
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.96010.00161449776885276.5034
2024-03-31Handelsbanken Hälsovård Tema (A1 SEK)0.72840.0408110000000
2024-01-31Fidelity Small Cap Index0.64210.0044969707139671.4614
2024-02-29Fidelity Select Biotechnology0.56580.019885434700
2023-06-30Jupiter Merian Glb Eq AbsRet I USD Acc0.53480.1246807568412086104.1984
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.410.0017619206106001.7417
2024-03-28iShares Russell 2000 Growth ETF0.37830.0038571195-664-0.1161
2024-02-29Fidelity Extended Market Index0.35580.0016537233-2603-0.4822
2023-12-31Vanguard Explorer Inv0.34380.00345191715191710
2024-03-29Schwab US Small-Cap ETF™0.30910.002146673700
2024-02-29Fidelity VIP Growth Initial0.26860.004740560000
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.2350.002835481400
2024-02-29Vanguard Health Care ETF0.23420.001935370917760.5046
2024-02-29Vanguard Russell 2000 ETF0.23120.0042349178277688.6394
Total 21.20970.267532028588+1071771+3.3%

3.3. Insider Transactions

Insiders are holding 5.679% of the shares of Seres Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-16David ArkowitzSELL39391.08
2024-02-16Eric D ShaffSELL115491.08
2024-02-16Teresa L YoungSELL33741.08
2023-10-30David ArkowitzSELL40661.35
2023-10-30Eric D ShaffSELL85521.35
2023-10-30Paula CloghessySELL29041.35
2023-10-30Thomas DesrosierSELL41561.35
2023-04-28David S EgeSELL70385.19

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Seres Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.197-0.092-53%-0.200+2%0.001-18747%-0.008-96%
Book Value Per Share---0.297-0.141-52%0.302-198%0.237-225%0.369-180%
Current Ratio--1.7782.382-25%2.713-34%3.079-42%6.703-73%
Debt To Asset Ratio--1.1251.072+5%0.854+32%0.981+15%0.798+41%
Debt To Equity Ratio---4.243-100%12.190-100%3.667-100%2.599-100%
Dividend Per Share----0%-0%-0%0.000-100%
Eps---0.273-0.188-31%-0.414+52%-0.195-29%-0.163-40%
Free Cash Flow Per Share---0.320-0.207-35%-0.395+23%-0.178-44%-0.119-63%
Free Cash Flow To Equity Per Share---0.278-0.089-68%-0.181-35%0.018-1666%0.023-1292%
Gross Profit Margin--1.0981.025+7%1.000+10%1.005+9%1.002+10%
Intrinsic Value_10Y_max---9.306--------
Intrinsic Value_10Y_min---15.413--------
Intrinsic Value_1Y_max---0.542--------
Intrinsic Value_1Y_min---0.941--------
Intrinsic Value_3Y_max---1.927--------
Intrinsic Value_3Y_min---3.366--------
Intrinsic Value_5Y_max---3.670--------
Intrinsic Value_5Y_min---6.364--------
Market Cap84549934.621-150%211412588.800537592011.520-61%852068237.360-75%1323065283.408-84%1646224526.288-87%
Net Profit Margin---644.500-165.248-74%-45.413-93%-45.083-93%-24.325-96%
Operating Margin---687.750-176.282-74%-44.160-94%-46.980-93%-25.301-96%
Operating Ratio--688.750175.974+291%45.713+1407%48.619+1317%28.316+2332%
Pb Ratio-1.885+60%-4.713-3.595-24%32.128-115%6.983-167%9.283-151%
Pe Ratio-0.512+60%-1.281-0.570-55%-3.465+170%-9.934+675%-18.228+1323%
Price Per Share0.560-150%1.4003.560-61%5.643-75%8.762-84%10.902-87%
Price To Free Cash Flow Ratio-0.437+60%-1.093-0.606-44%-3.524+223%-10.339+846%-20.583+1784%
Price To Total Gains Ratio-2.844+60%-7.110-5.242-26%-5.833-18%-42.059+492%-111.912+1474%
Quick Ratio--1.3852.160-36%3.163-56%3.835-64%10.427-87%
Return On Assets---0.115-0.099-14%-0.204+77%-0.129+12%-0.176+53%
Return On Equity---0.515-100%-2.7260%-0.4910%-0.5650%
Total Gains Per Share---0.197-0.092-53%-0.200+2%0.001-18747%-0.007-96%
Usd Book Value---44856000.000-21309000.000-52%45595500.000-198%35819800.000-225%55735550.000-180%
Usd Book Value Change Per Share---0.197-0.092-53%-0.200+2%0.001-18747%-0.008-96%
Usd Book Value Per Share---0.297-0.141-52%0.302-198%0.237-225%0.369-180%
Usd Dividend Per Share----0%-0%-0%0.000-100%
Usd Eps---0.273-0.188-31%-0.414+52%-0.195-29%-0.163-40%
Usd Free Cash Flow---48376000.000-31332250.000-35%-59659250.000+23%-26928350.000-44%-17942325.000-63%
Usd Free Cash Flow Per Share---0.320-0.207-35%-0.395+23%-0.178-44%-0.119-63%
Usd Free Cash Flow To Equity Per Share---0.278-0.089-68%-0.181-35%0.018-1666%0.023-1292%
Usd Market Cap84549934.621-150%211412588.800537592011.520-61%852068237.360-75%1323065283.408-84%1646224526.288-87%
Usd Price Per Share0.560-150%1.4003.560-61%5.643-75%8.762-84%10.902-87%
Usd Profit---41248000.000-28582500.000-31%-63456000.000+54%-29656900.000-28%-23613250.000-43%
Usd Revenue--64000.00031581250.000-100%1782000.000-96%17305000.000-100%10705800.000-99%
Usd Total Gains Per Share---0.197-0.092-53%-0.200+2%0.001-18747%-0.007-96%
 EOD+2 -6MRQTTM+6 -28YOY+15 -185Y+6 -2710Y+6 -29

4.2. Fundamental Score

Let's check the fundamental score of Seres Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.512
Price to Book Ratio (EOD)Between0-1-1.885
Net Profit Margin (MRQ)Greater than0-644.500
Operating Margin (MRQ)Greater than0-687.750
Quick Ratio (MRQ)Greater than11.385
Current Ratio (MRQ)Greater than11.778
Debt to Asset Ratio (MRQ)Less than11.125
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.115
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Seres Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.421
Ma 20Greater thanMa 500.706
Ma 50Greater thanMa 1000.881
Ma 100Greater thanMa 2001.034
OpenGreater thanClose0.580
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets358,600
Total Liabilities403,456
Total Stockholder Equity-44,856
 As reported
Total Liabilities 403,456
Total Stockholder Equity+ -44,856
Total Assets = 358,600

Assets

Total Assets358,600
Total Current Assets175,410
Long-term Assets183,190
Total Current Assets
Cash And Cash Equivalents 127,965
Net Receivables 8,674
Inventory 29,647
Other Current Assets 9,124
Total Current Assets  (as reported)175,410
Total Current Assets  (calculated)175,410
+/-0
Long-term Assets
Property Plant Equipment 132,250
Long-term Assets Other 41,354
Long-term Assets  (as reported)183,190
Long-term Assets  (calculated)173,604
+/- 9,586

Liabilities & Shareholders' Equity

Total Current Liabilities98,659
Long-term Liabilities304,797
Total Stockholder Equity-44,856
Total Current Liabilities
Short-term Debt 6,677
Accounts payable 3,641
Other Current Liabilities 80,611
Total Current Liabilities  (as reported)98,659
Total Current Liabilities  (calculated)90,929
+/- 7,730
Long-term Liabilities
Long term Debt 101,544
Capital Lease Obligations 112,392
Long-term Liabilities Other 1,628
Long-term Liabilities  (as reported)304,797
Long-term Liabilities  (calculated)215,564
+/- 89,233
Total Stockholder Equity
Common Stock135
Retained Earnings -978,235
Other Stockholders Equity 933,244
Total Stockholder Equity (as reported)-44,856
Total Stockholder Equity (calculated)-44,856
+/-0
Other
Capital Stock135
Cash and Short Term Investments 127,965
Common Stock Shares Outstanding 129,262
Current Deferred Revenue7,730
Liabilities and Stockholders Equity 358,600
Net Debt 85,971
Net Invested Capital 56,688
Net Working Capital 76,751
Property Plant and Equipment Gross 183,388
Short Long Term Debt Total 213,936



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
2,125
0
0
8,553
117,345
108,628
101,281
227,045
216,900
324,468
306,217
297,514
272,646
244,850
216,339
211,882
189,522
159,433
132,954
109,042
120,472
107,042
146,093
124,151
132,440
110,619
100,678
356,201
342,940
305,695
269,648
396,293
354,859
319,889
273,196
311,868
348,784
270,194
406,387
367,699
358,600
358,600367,699406,387270,194348,784311,868273,196319,889354,859396,293269,648305,695342,940356,201100,678110,619132,440124,151146,093107,042120,472109,042132,954159,433189,522211,882216,339244,850272,646297,514306,217324,468216,900227,045101,281108,628117,3458,553002,125
   > Total Current Assets 
1,705
1,654
0
7,409
114,243
105,084
94,064
222,363
207,610
306,846
217,103
208,434
198,369
192,261
176,051
176,645
155,078
126,454
101,537
79,446
92,665
67,755
108,994
89,578
100,189
80,563
72,716
308,010
268,777
251,978
224,555
358,811
303,628
263,250
209,580
247,513
194,764
116,081
251,238
214,394
175,410
175,410214,394251,238116,081194,764247,513209,580263,250303,628358,811224,555251,978268,777308,01072,71680,563100,18989,578108,99467,75592,66579,446101,537126,454155,078176,645176,051192,261198,369208,434217,103306,846207,610222,36394,064105,084114,2437,40901,6541,705
       Cash And Cash Equivalents 
1,654
-1,654
0
7,120
114,185
45,045
36,338
69,702
73,933
193,228
59,824
55,611
54,539
41,899
33,642
46,025
36,088
47,194
57,960
55,713
85,820
53,600
102,230
49,296
65,126
54,857
61,536
207,326
116,049
66,579
73,997
227,460
180,002
153,192
126,824
205,398
163,030
94,841
229,520
169,912
127,965
127,965169,912229,52094,841163,030205,398126,824153,192180,002227,46073,99766,579116,049207,32661,53654,85765,12649,296102,23053,60085,82055,71357,96047,19436,08846,02533,64241,89954,53955,61159,824193,22873,93369,70236,33845,045114,1857,1200-1,6541,654
       Short-term Investments 
0
3,308
0
0
131,149
59,271
55,438
149,641
131,149
110,050
152,032
147,768
138,704
145,174
137,570
125,274
113,895
75,000
38,106
17,177
0
0
0
34,492
29,690
20,237
2,404
90,588
137,567
176,221
140,556
119,927
110,704
94,809
68,971
27,605
18,311
11,703
0
0
0
00011,70318,31127,60568,97194,809110,704119,927140,556176,221137,56790,5882,40420,23729,69034,49200017,17738,10675,000113,895125,274137,570145,174138,704147,768152,032110,050131,149149,64155,43859,271131,149003,3080
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
297
297
297
510
175
175
217
0
6,667
1,604
1,717
1,785
2,084
2,929
3,393
9,387
2,604
1,251
1,250
0
0
0
0
0
0
7,559
16,857
8,674
8,67416,8577,5590000001,2501,2512,6049,3873,3932,9292,0841,7851,7171,6046,66702171751755102972972970000000000000
       Other Current Assets 
51
0
0
289
58
768
2,288
3,020
2,528
3,568
5,247
5,055
5,126
5,188
4,839
5,346
5,095
4,260
5,471
6,556
6,845
7,488
5,160
4,073
3,588
3,385
5,847
6,703
5,774
6,574
8,751
10,174
12,922
15,249
13,785
14,510
13,423
9,537
8,819
9,100
9,124
9,1249,1008,8199,53713,42314,51013,78515,24912,92210,1748,7516,5745,7746,7035,8473,3853,5884,0735,1607,4886,8456,5565,4714,2605,0955,3464,8395,1885,1265,0555,2473,5682,5283,0202,288768582890051
   > Long-term Assets 
352
0
0
866
3,102
3,544
7,217
4,682
9,290
17,622
89,114
89,080
74,277
52,589
40,288
35,237
34,444
32,979
31,417
29,596
27,807
39,287
37,099
34,573
32,251
30,056
27,962
48,191
74,163
53,717
45,093
37,482
51,231
56,639
63,616
64,355
154,020
154,113
155,149
153,305
183,190
183,190153,305155,149154,113154,02064,35563,61656,63951,23137,48245,09353,71774,16348,19127,96230,05632,25134,57337,09939,28727,80729,59631,41732,97934,44435,23740,28852,58974,27789,08089,11417,6229,2904,6827,2173,5443,10286600352
       Property Plant Equipment 
352
0
0
866
1,264
1,313
3,319
4,543
7,751
16,082
26,985
34,560
36,125
36,089
34,813
33,724
32,931
31,466
29,904
28,083
26,294
37,773
35,585
33,059
30,851
28,656
26,562
24,393
22,938
21,966
27,462
28,943
36,146
45,312
44,521
43,231
133,969
133,220
134,309
131,671
132,250
132,250131,671134,309133,220133,96943,23144,52145,31236,14628,94327,46221,96622,93824,39326,56228,65630,85133,05935,58537,77326,29428,08329,90431,46632,93133,72434,81336,08936,12534,56026,98516,0827,7514,5433,3191,3131,26486600352
       Long Term Investments 
0
0
0
0
36,752
0
0
0
0
0
60,589
53,098
36,752
15,099
3,962
0
0
0
0
0
0
1,400
1,400
1,400
1,400
1,400
0
22,398
49,825
29,749
14,879
5,788
495
0
0
0
0
0
0
0
0
000000004955,78814,87929,74949,82522,39801,4001,4001,4001,4001,4000000003,96215,09936,75253,09860,5890000036,7520000
       Other Assets 
68
0
0
278
1,838
2,231
3,898
139
1,539
1,540
62,129
54,520
38,152
16,500
5,475
1,513
1,513
1,513
1,513
1,513
1,513
1,514
1,514
1,514
1,400
1,400
1,400
1,400
60,266
2,002
2,752
2,751
14,590
11,327
19,095
21,124
20,051
0
20,840
0
0
0020,840020,05121,12419,09511,32714,5902,7512,7522,00260,2661,4001,4001,4001,4001,5141,5141,5141,5131,5131,5131,5131,5131,5135,47516,50038,15254,52062,1291,5401,5391393,8982,2311,8382780068
> Total Liabilities 
1,494
0
0
4,365
144,066
4,451
6,368
4,846
11,506
134,639
138,821
143,517
140,015
133,397
128,410
126,370
128,823
149,400
146,209
139,607
168,517
176,875
164,061
156,370
180,764
172,268
166,253
168,149
168,190
161,990
168,582
220,555
223,352
238,933
250,138
244,283
338,001
318,065
383,773
382,822
403,456
403,456382,822383,773318,065338,001244,283250,138238,933223,352220,555168,582161,990168,190168,149166,253172,268180,764156,370164,061176,875168,517139,607146,209149,400128,823126,370128,410133,397140,015143,517138,821134,63911,5064,8466,3684,451144,0664,365001,494
   > Total Current Liabilities 
1,056
0
0
2,777
5,103
3,435
5,641
4,846
10,920
24,822
27,331
31,878
30,457
27,244
25,665
27,032
31,625
35,150
36,771
39,010
42,041
41,569
43,073
42,237
45,993
44,114
44,248
45,770
46,415
47,863
56,165
94,591
82,258
82,359
89,037
81,819
85,596
63,818
77,898
79,225
98,659
98,65979,22577,89863,81885,59681,81989,03782,35982,25894,59156,16547,86346,41545,77044,24844,11445,99342,23743,07341,56942,04139,01036,77135,15031,62527,03225,66527,24430,45731,87827,33124,82210,9204,8465,6413,4355,1032,777001,056
       Short-term Debt 
0
0
0
0
1,200
1,200
1,200
0
0
6,906
10,744
15,512
7,496
6,806
6,975
6,779
9,216
8,857
10,750
11,833
12,066
4,407
4,449
4,335
4,456
4,623
4,788
4,950
5,569
8,589
11,973
15,444
6,610
6,849
7,058
7,333
4,057
4,784
5,470
6,280
6,677
6,6776,2805,4704,7844,0577,3337,0586,8496,61015,44411,9738,5895,5694,9504,7884,6234,4564,3354,4494,40712,06611,83310,7508,8579,2166,7796,9756,8067,49615,51210,7446,906001,2001,2001,2000000
       Short Long Term Debt 
0
0
0
0
1,200
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,407
0
0
0
0
0
0
454
3,339
6,298
9,345
0
0
0
0
456
0
0
0
0
000045600009,3456,2983,3394540000004,40700000000000000001,2000000
       Accounts payable 
393
0
0
1,009
2,166
1,109
1,688
2,089
5,397
5,763
4,454
4,228
7,587
5,636
3,889
5,380
7,033
5,418
5,158
6,475
6,415
3,918
4,764
4,455
4,859
5,521
4,163
6,201
4,018
4,879
5,450
8,623
13,735
6,791
13,992
10,449
17,440
12,297
12,922
8,958
3,641
3,6418,95812,92212,29717,44010,44913,9926,79113,7358,6235,4504,8794,0186,2014,1635,5214,8594,4554,7643,9186,4156,4755,1585,4187,0335,3803,8895,6367,5874,2284,4545,7635,3972,0891,6881,1092,1661,00900393
       Other Current Liabilities 
663
0
0
1,768
278
271
517
2,757
5,523
153
121
111
3,316
2,744
2,743
2,815
3,297
3,016
2,901
2,801
3,141
11,789
10,589
10,522
10,884
9,141
10,604
11,318
14,226
13,153
18,913
48,900
45,094
48,278
56,889
59,169
59,840
44,361
55,878
54,158
80,611
80,61154,15855,87844,36159,84059,16956,88948,27845,09448,90018,91313,15314,22611,31810,6049,14110,88410,52210,58911,7893,1412,8012,9013,0163,2972,8152,7432,7443,3161111211535,5232,7575172712781,76800663
   > Long-term Liabilities 
438
0
0
1,588
138,963
1,016
727
0
586
109,817
111,490
111,639
109,558
106,153
102,745
99,338
97,198
114,250
109,438
100,597
126,476
135,306
120,988
114,133
134,771
128,154
122,005
122,379
121,775
114,127
112,417
125,964
141,094
156,574
161,101
162,464
252,405
254,247
305,875
303,597
304,797
304,797303,597305,875254,247252,405162,464161,101156,574141,094125,964112,417114,127121,775122,379122,005128,154134,771114,133120,988135,306126,476100,597109,438114,25097,19899,338102,745106,153109,558111,639111,490109,81758607271,016138,9631,58800438
       Long term Debt Total 
0
0
0
0
0
0
727
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,648
24,754
24,863
24,977
24,639
21,872
19,036
16,117
24,643
50,437
50,632
50,857
50,591
51,234
0
0
0
00051,23450,59150,85750,63250,43724,64316,11719,03621,87224,63924,97724,86324,75424,64800000000000000000727000000
       Long term Debt 
438
0
0
0
1,304
1,016
727
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,066
0
0
24,648
24,754
24,863
24,977
24,639
21,872
19,036
16,117
24,643
50,437
50,632
50,857
50,591
51,234
100,742
101,135
101,544
101,544101,135100,74251,23450,59150,85750,63250,43724,64316,11719,03621,87224,63924,97724,86324,75424,6480019,066000000000000007271,0161,304000438
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-1,200
-1,200
-1,200
0
0
-6,906
-10,744
-15,512
-7,496
-6,806
-6,975
-6,779
-9,216
-8,857
-10,750
-11,833
-12,066
19,066
17,969
16,844
15,676
14,444
13,181
11,894
10,107
5,855
7,530
2,886
17,958
20,346
19,516
17,850
107,486
106,692
106,706
104,863
105,715
105,715104,863106,706106,692107,48617,85019,51620,34617,9582,8867,5305,85510,10711,89413,18114,44415,67616,84417,96919,066-12,066-11,833-10,750-8,857-9,216-6,779-6,975-6,806-7,496-15,512-10,744-6,90600-1,200-1,200-1,2000000
       Other Liabilities 
164
0
0
0
1,582
1,369
0
0
586
109,817
111,490
111,639
109,558
106,153
102,745
99,338
97,198
114,250
109,438
100,597
126,476
116,240
103,019
97,289
94,447
88,956
83,961
85,508
86,575
83,061
79,553
97,616
98,493
85,791
90,953
93,757
93,872
0
98,427
0
0
0098,427093,87293,75790,95385,79198,49397,61679,55383,06186,57585,50883,96188,95694,44797,289103,019116,240126,476100,597109,438114,25097,19899,338102,745106,153109,558111,639111,490109,817586001,3691,582000164
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
586
109,817
111,490
110,258
107,486
104,036
100,586
97,136
94,965
112,016
107,207
98,368
124,260
135,306
120,988
114,133
110,123
103,400
97,142
97,402
97,136
92,255
1,119
109,847
116,451
106,137
110,469
111,607
201,814
203,013
1,532
1,579
1,628
1,6281,5791,532203,013201,814111,607110,469106,137116,451109,8471,11992,25597,13697,40297,142103,400110,123114,133120,988135,306124,26098,368107,207112,01694,96597,136100,586104,036107,486110,258111,490109,81758600000000
       Deferred Long Term Liability 
0
0
0
0
1,699
0
0
0
0
0
0
1,381
2,072
2,117
2,159
2,202
2,233
2,234
2,231
2,229
2,216
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000002,2162,2292,2312,2342,2332,2022,1592,1172,0721,3810000001,6990000
> Total Stockholder Equity
631
631
0
4,188
-26,721
104,177
94,913
222,199
205,394
189,829
167,396
153,997
132,631
111,453
87,929
85,512
60,699
10,033
-13,255
-30,565
-48,045
-69,833
-17,968
-32,219
-48,324
-61,649
-65,575
188,052
174,750
143,705
101,066
175,738
131,507
80,956
23,058
67,585
10,783
-47,871
22,614
-15,123
-44,856
-44,856-15,12322,614-47,87110,78367,58523,05880,956131,507175,738101,066143,705174,750188,052-65,575-61,649-48,324-32,219-17,968-69,833-48,045-30,565-13,25510,03360,69985,51287,929111,453132,631153,997167,396189,829205,394222,19994,913104,177-26,7214,1880631631
   Common Stock
7
0
0
7
7
30
31
39
39
39
40
40
40
40
40
40
40
40
40
41
41
41
70
70
70
72
75
91
91
92
92
92
92
92
92
124
125
127
128
129
135
13512912812712512492929292929291917572707070414141404040404040404040393939313077007
   Retained Earnings Total Equity000-935,685-864,511-795,715-735,713-670,978-614,354-564,353-632,571-584,241-548,776-530,524-500,244-479,530-459,649-440,871-424,462-413,703-389,370-368,083-346,136-318,347-263,571-234,618-227,683-199,665-174,191-148,915-130,229-102,316-82,612-62,978-48,358000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-283
31
23
-10
30
108
83
-67
-149
-151
-176
-99
-146
-106
-29
-9
-20,301
-22,146
-24,066
7
-27,742
-10
1
2
-47
-15
12
11
-60
-215
-256
-118
-12
2
-1
0
0
00-12-12-118-256-215-601112-15-4721-10-27,7427-24,066-22,146-20,301-9-29-106-146-99-176-151-149-678310830-102331-2830000
   Capital Surplus 
0
0
0
0
0
0
143,217
285,148
287,937
291,998
297,502
302,939
306,931
311,229
315,748
320,189
324,376
328,446
332,870
337,486
341,284
343,829
406,424
408,575
411,255
417,819
434,593
718,483
723,482
727,869
733,533
739,988
745,829
752,057
758,935
863,294
875,181
887,685
0
0
0
000887,685875,181863,294758,935752,057745,829739,988733,533727,869723,482718,483434,593417,819411,255408,575406,424343,829341,284337,486332,870328,446324,376320,189315,748311,229306,931302,939297,502291,998287,937285,148143,217000000
   Treasury Stock00000000000000000000000000000000000000000
   Other Stockholders Equity 
0
-11,116
0
3
1,387
140,325
41,936
58,103
288,978
293,503
299,820
306,358
311,962
317,988
324,243
330,626
336,669
342,720
349,175
355,785
361,585
365,975
430,490
434,524
438,997
447,353
465,829
751,296
723,482
727,869
733,533
739,988
745,829
752,057
758,935
863,294
875,181
887,685
911,620
921,735
933,244
933,244921,735911,620887,685875,181863,294758,935752,057745,829739,988733,533727,869723,482751,296465,829447,353438,997434,524430,490365,975361,585355,785349,175342,720336,669330,626324,243317,988311,962306,358299,820293,503288,97858,10341,936140,3251,38730-11,1160



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue126,325
Cost of Revenue-15,114
Gross Profit111,211111,211
 
Operating Income (+$)
Gross Profit111,211
Operating Expense-218,490
Operating Income-107,279-107,279
 
Operating Expense (+$)
Research Development145,860
Selling General Administrative87,744
Selling And Marketing Expenses0
Operating Expense218,490233,604
 
Net Interest Income (+$)
Interest Income6,744
Interest Expense-13,176
Other Finance Cost-2,149
Net Interest Income-4,283
 
Pretax Income (+$)
Operating Income-107,279
Net Interest Income-4,283
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-113,724-100,834
EBIT - interestExpense = -120,455
-113,724
-100,548
Interest Expense13,176
Earnings Before Interest and Taxes (EBIT)-107,279-100,548
Earnings Before Interest and Taxes (EBITDA)-92,165
 
After tax Income (+$)
Income Before Tax-113,724
Tax Provision-0
Net Income From Continuing Ops-141,272-113,724
Net Income-113,724
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses233,604
Total Other Income/Expenses Net-6,4454,283
 

Technical Analysis of Seres Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Seres Therapeutics Inc. The general trend of Seres Therapeutics Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Seres Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Seres Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.91 < 0.9152 < 1.01.

The bearish price targets are: .

Tweet this
Seres Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Seres Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Seres Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Seres Therapeutics Inc. The current macd is -0.08043347.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Seres Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Seres Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Seres Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Seres Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartSeres Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Seres Therapeutics Inc. The current adx is 40.47.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Seres Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Seres Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Seres Therapeutics Inc. The current sar is 0.70485369.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Seres Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Seres Therapeutics Inc. The current rsi is 24.42. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Seres Therapeutics Inc Daily Relative Strength Index (RSI) ChartSeres Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Seres Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Seres Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Seres Therapeutics Inc Daily Stochastic Oscillator ChartSeres Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Seres Therapeutics Inc. The current cci is -156.92053977.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Seres Therapeutics Inc Daily Commodity Channel Index (CCI) ChartSeres Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Seres Therapeutics Inc. The current cmo is -62.83633618.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Seres Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartSeres Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Seres Therapeutics Inc. The current willr is -92.05588822.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Seres Therapeutics Inc Daily Williams %R ChartSeres Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Seres Therapeutics Inc.

Seres Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Seres Therapeutics Inc. The current atr is 0.05904333.

Seres Therapeutics Inc Daily Average True Range (ATR) ChartSeres Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Seres Therapeutics Inc. The current obv is -210,273,412.

Seres Therapeutics Inc Daily On-Balance Volume (OBV) ChartSeres Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Seres Therapeutics Inc. The current mfi is 20.68.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Seres Therapeutics Inc Daily Money Flow Index (MFI) ChartSeres Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Seres Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Seres Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Seres Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.421
Ma 20Greater thanMa 500.706
Ma 50Greater thanMa 1000.881
Ma 100Greater thanMa 2001.034
OpenGreater thanClose0.580
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Seres Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Seres Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Seres Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Seres Therapeutics Inc

I send you an email if I find something interesting about Seres Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Seres Therapeutics Inc.

Receive notifications about Seres Therapeutics Inc in your mailbox!